• NF 449 (SKU B6716): Precision Purinergic Antagonism in Plate

  2026-06-12

  This article guides biomedical researchers through practical laboratory scenarios where NF 449 (SKU B6716) addresses challenges in platelet activation, aggregation, and G protein signaling assays. Scenario-driven Q&A blocks illustrate how this purinergic receptor antagonist, supplied by APExBIO, delivers selectivity, reproducibility, and workflow confidence for antithrombotic research applications.

• Tacalcitol Monohydrate: Synthetic Analog of Vitamin D3 for R

  2026-06-11

  Tacalcitol monohydrate is a synthetic analog of vitamin D3 with proven efficacy as a topical treatment for psoriasis vulgaris and as an inducer of nerve growth factor (NGF) in keratinocytes. It offers enhanced safety and robust gene regulatory effects, making it valuable in dermatological and colorectal cancer research.

• Bradykinin B2 Receptors Inhibit Peristaltic Reflex in Guinea

  2026-06-11

  This study provides the first direct evidence that bradykinin B2 receptors mediate inhibition of the peristaltic reflex in the guinea pig ileum. These findings clarify kininergic signaling in gastrointestinal motility and establish a mechanistic basis for further exploration of bradykinin-ACE interactions in translational research.

• Disrupting the CBFβ-SMMHC Axis: AI-10-49 and the Future of A

  2026-06-10

  This thought-leadership article explores the mechanistic and translational significance of targeting the CBFβ-SMMHC fusion oncoprotein in inv(16) acute myeloid leukemia (AML), with a focus on the selective inhibitor AI-10-49. By weaving together emerging biological insights—particularly the newly elucidated N-MYC/eIF4G1 axis—with actionable experimental strategies, the piece positions AI-10-49 both as a powerful research tool and as a catalyst for next-generation AML therapy development. The discussion is grounded in recent high-impact research, with direct reference to landmark studies and APExBIO’s product leadership.

• LAMP1 Modulates CXCL10-CXCR3 Axis in Macrophage Polarization

  2026-06-10

  This study reveals that LAMP1 acts as a molecular switch for the CXCL10-CXCR3 axis, dictating macrophage polarization in inflammatory versus non-inflammatory states. The findings demonstrate how CXCR3 antagonism, including with AMG 487, can reprogram macrophage phenotypes and mitigate acute lung injury, offering new mechanistic insight for inflammation research.

• GPC3-HSP70 mRNA Nanovaccine and PD-L1 Blockade in HCC Immuno

  2026-06-09

  This study introduces a nanovaccine platform encoding GPC3-derived T cell epitopes fused to HSP70, achieving robust antigen-specific immunity against hepatocellular carcinoma (HCC). The combination with anti-PD-L1 therapy leads to synergistic antitumor effects, highlighting a promising strategy for overcoming immunosuppression in advanced liver cancer.

• Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI

  2026-06-09

  A recent study demonstrates that mannose-modified lipid nanoparticles can deliver human erythropoietin mRNA directly to inflammatory macrophages at spinal cord injury sites, enabling local EPO protein synthesis. This targeted approach attenuates neuroinflammation and ferroptosis, resulting in improved neurological recovery and advancing mRNA-based neurorepair strategies.

• Artesunate: Applied Workflows in Cancer Research and Optimiz

  2026-06-08

  Artesunate, a potent artemisinin derivative, enables cutting-edge in vitro oncology research through targeted AKT/mTOR pathway inhibition and ferroptosis induction. This guide translates recent mechanistic advances and reference-driven workflows into actionable protocols and troubleshooting strategies for maximizing assay fidelity.

• Methyl-β-cyclodextrin: Protocol Parameters and QC for Membra

  2026-06-08

  Methyl-β-cyclodextrin enables selective extraction of cholesterol and certain lipids from cellular membranes, supporting research into membrane fluidity, lipid raft disruption, and cholesterol-dependent pathways. It is designed for laboratory workflows requiring precise membrane modulation and is not suitable for diagnostic or medical use. Proper storage and solution handling are essential to maintain reagent integrity.

• Wortmannin: Selective PI3K Inhibitor for Cancer and Autophag

  2026-06-07

  Wortmannin is a potent, selective, and irreversible PI3K inhibitor widely used in cancer and autophagy research. Its nanomolar potency and specificity make it an essential tool for dissecting PI3K/Akt/mTOR signaling pathways and related cellular processes. The compound’s benchmarked efficacy, solubility profile, and protocol parameters are well defined for academic and translational workflows.

• Veratridine: Voltage-Gated Sodium Channel Opener in Action

  2026-06-06

  Veratridine’s precise action as a voltage-gated sodium channel opener enables robust modeling of excitotoxicity, sodium channel dynamics, and targeted chemosensitivity in both neuroscience and cancer research. APExBIO’s validated Veratridine (CAS: 71-62-5) empowers reproducible, high-fidelity results across cell, tissue, and animal workflows.

• Non-Canonical Dlat-Trpv3 Thermogenesis Pathway in Obesity Co

  2026-06-05

  This study reveals that hyperforin activates adipose thermogenesis through a Dlat-Trpv3-AMPK pathway, independent of the traditional β3-adrenergic mechanism. The findings provide a mechanistic basis for developing safer anti-obesity strategies targeting non-canonical thermogenic signaling.

• ML385: Precision NRF2 Inhibitor Strategies for Cancer & Live

  2026-06-05

  ML385 stands out as a selective NRF2 inhibitor, enabling researchers to dissect oxidative stress, therapeutic resistance, and ferroptosis in cancer and liver disease models. This article delivers protocol-driven insights, troubleshooting tips, and evidence-backed workflows to maximize data reliability with ML385 from APExBIO.

• Berberine Hydrochloride for Metabolic Disease Research: Prot

  2026-06-04

  Berberine hydrochloride stands out as a multipurpose tool in metabolic and cancer research, offering robust activation of AMPK and precise modulation of lipid metabolism. Applied workflows, advanced troubleshooting, and insights from recent cardioprotection studies elevate its value for translational scientists tackling diabetes, obesity, and cardiovascular disease models.

• Panobinostat (LBH589): Advanced HDACi Workflows for Cancer R

  2026-06-04

  Panobinostat (LBH589) empowers researchers with a potent, broad-spectrum HDAC inhibitor for dissecting apoptosis and epigenetic regulation in cancer models. This guide demystifies experimental workflows, troubleshooting, and next-level applications, integrating breakthrough mechanistic insights and real-world protocol enhancements.

408 records 12/28 page Previous Next First page 上5页 1112131415 下5页 Last page